I'd like to see a combination of the two. PPS stops BME and halts or slows Cartilage degradation while past stem cell therapies seem to have targeted cartilage regrowth. What is interesting is that the exec at PAR are ex-MSB, where this drug and its interaction with stem cells was studied. With PPS fast becoming the standard of care for knee OA wouldn't it be nice if they could prove better efficacy in combination with stem cells.
W
Osteoarthrities paper, page-8
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.015(6.12%) |
Mkt cap ! $46.70M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.5¢ | 26.0¢ | $19.61K | 74.78K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38426 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 1862 | 1 |
View Market Depth
| Last trade - 12.12pm 15/05/2024 (20 minute delay) ? |
|
|||||
|
Last
27.5¢ |
Change
0.015 ( 12.2 %) |
||||
| Open | High | Low | Volume | ||
| 26.5¢ | 27.5¢ | 26.5¢ | 20598 | ||
| Last updated 12.23pm 15/05/2024 ? | |||||
| CYP (ASX) Chart |